{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T04:07:45Z","timestamp":1751861265825,"version":"3.41.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Health","award":["R01 MH123267"],"award-info":[{"award-number":["R01 MH123267"]}]},{"name":"NIH","award":["NIH T32 AI07140."],"award-info":[{"award-number":["NIH T32 AI07140."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10461-025-04687-x","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:11:09Z","timestamp":1742965869000},"page":"2234-2242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Preference for Injectable Pre-exposure Prophylaxis among Young Women in Kenya"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-733X","authenticated-orcid":false,"given":"Kidist","family":"Zewdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kinuthia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Matemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Wandera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valarie","family":"Kemunto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Cherotich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tecy","family":"Oyambra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Achieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Odhiambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Oduor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Sajita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cole","family":"Grabow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Heffron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth K.","family":"Mugwanya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,24]]},"reference":[{"key":"4687_CR1","unstructured":"UNAFact sheet - Latest global and regional statistics on the status of the AIDS epidemic. 2023.https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/UNAIDS_FactSheet (accessed 28 Feb2024)."},{"key":"4687_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/QAI.0000000000000172","volume":"66","author":"D Donnell","year":"2014","unstructured":"Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of Tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 1999. 2014;66:340\u20138.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"4687_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV-1 prevention among heterosexual men and women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"4687_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1402269","volume":"372","author":"JM Marrazzo","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-Based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509\u201318.","journal-title":"N Engl J Med"},{"key":"4687_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Van Damme","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411\u201322.","journal-title":"N Engl J Med"},{"key":"4687_CR6","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/QAI.0000000000000158","volume":"66","author":"AL Corneli","year":"2014","unstructured":"Corneli AL, Deese J, Wang M, Taylor D, Ahmed K, Agot K, et al. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for Pre-exposure prophylaxis. J Acquir Immune Defic Syndr 1999. 2014;66:324\u201331.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"4687_CR7","doi-asserted-by":"publisher","unstructured":"Celum CL, Delany-Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA, et al. HIV pre\u2010exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22. https:\/\/doi.org\/10.1002\/jia2.25298.","DOI":"10.1002\/jia2.25298"},{"key":"4687_CR8","doi-asserted-by":"publisher","first-page":"e25636","DOI":"10.1002\/jia2.25636","volume":"23","author":"CL Celum","year":"2020","unstructured":"Celum CL, Gill K, Morton JF, Stein G, Myers L, Thomas KK, et al. Incentives conditioned on Tenofovir levels to support PrEP adherence among young South African women: a randomized trial. J Int AIDS Soc. 2020;23:e25636.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR9","doi-asserted-by":"publisher","first-page":"e1003670","DOI":"10.1371\/journal.pmed.1003670","volume":"18","author":"C Celum","year":"2021","unstructured":"Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in Southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18:e1003670.","journal-title":"PLoS Med"},{"key":"4687_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/QAI.0000000000001574","volume":"77","author":"A Cabral","year":"2018","unstructured":"Cabral A, Baeten J, Ngure K, Velloza J, Odoyo J, Haberer J, et al. Intimate partner violence and self-reported pre-exposure prophylaxis (PrEP) interruptions among HIV-negative partners in HIV serodiscordant couples in Kenya and Uganda. J Acquir Immune Defic Syndr 1999. 2018;77:154\u20139.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"4687_CR11","doi-asserted-by":"publisher","first-page":"e89118","DOI":"10.1371\/journal.pone.0089118","volume":"9","author":"A van der Straten","year":"2014","unstructured":"van der Straten A, Stadler J, Montgomery E, Hartmann M, Magazi B, Mathebula F, et al. Women\u2019s experiences with oral and vaginal Pre-Exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9:e89118.","journal-title":"PLoS ONE"},{"key":"4687_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/QAI.0000000000001093","volume":"73","author":"ST Roberts","year":"2016","unstructured":"Roberts ST, Haberer J, Celum C, Mugo N, Ware NC, Cohen CR, et al. Intimate partner violence and adherence to HIV Pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: A prospective cohort study. J Acquir Immune Defic Syndr 1999. 2016;73:313\u201322.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"4687_CR13","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and efficacy of a Dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133\u201343.","journal-title":"N Engl J Med"},{"key":"4687_CR14","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing Dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121\u201332.","journal-title":"N Engl J Med"},{"key":"4687_CR15","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","volume":"8","author":"JM Baeten","year":"2021","unstructured":"Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, et al. Safety, uptake, and use of a Dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV. 2021;8:e87\u201395.","journal-title":"Lancet HIV"},{"key":"4687_CR16","doi-asserted-by":"publisher","first-page":"e25634","DOI":"10.1002\/jia2.25634","volume":"23","author":"ER Brown","year":"2020","unstructured":"Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, et al. Greater Dapivirine release from the Dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23:e25634.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR17","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2352-3018(20)30300-3","volume":"8","author":"A Nel","year":"2021","unstructured":"Nel A, van Niekerk N, Van Baelen B, Malherbe M, Mans W, Carter A, et al. Safety, adherence, and HIV-1 seroconversion among women using the Dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV. 2021;8:e77\u201386.","journal-title":"Lancet HIV"},{"key":"4687_CR18","unstructured":"WHO recommends the dapivirine. vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. https:\/\/www.who.int\/news\/item\/26-01-2021-who-recommends-the-dapivirine-vaginal-ring-as-a-new-choice-for-hiv-prevention-for-women-at-substantial-risk-of-hiv-infection (accessed 19 Jul2021)."},{"key":"4687_CR19","unstructured":"BUCKINGHAM L. Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden. Eur. Med. Agency. 2020 (Accessed 5 Oct2 021)."},{"key":"4687_CR20","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331\u201340.","journal-title":"Lancet HIV"},{"key":"4687_CR21","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, G\u00f3rgolas Hern\u00e1ndez-Mora M, Pokrovsky V, Overton ET, Girard P-M, et al. Long-Acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382:1124\u201335.","journal-title":"N Engl J Med"},{"key":"4687_CR22","doi-asserted-by":"publisher","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","volume":"15","author":"RJ Landovitz","year":"2018","unstructured":"Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.","journal-title":"PLoS Med"},{"key":"4687_CR23","doi-asserted-by":"publisher","first-page":"e25408","DOI":"10.1002\/jia2.25408","volume":"22","author":"EE Tolley","year":"2019","unstructured":"Tolley EE, Li S, Zangeneh SZ, Atujuna M, Musara P, Justman J, et al. Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical trial (HPTN 076). J Int AIDS Soc. 2019;22:e25408.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR24","unstructured":"Commissioner O. of the. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. FDA. 2021.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention (accessed 13 Jan2022)."},{"key":"4687_CR25","unstructured":"Injectable CAB. for PrEP. PrEPWatch. https:\/\/www.prepwatch.org\/products\/injectable-cab-for-prep\/ (accessed 12 Apr2023)."},{"key":"4687_CR26","doi-asserted-by":"publisher","first-page":"19157","DOI":"10.7448\/IAS.17.3.19157","volume":"17","author":"N Mack","year":"2014","unstructured":"Mack N, Evens EM, Tolley EE, Brelsford K, Mackenzie C, Milford C, et al. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study. J Int AIDS Soc. 2014;17:19157.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.9745\/GHSP-D-13-00010","volume":"1","author":"J Ross","year":"2013","unstructured":"Ross J, Stover J. Use of modern contraception increases when more methods become available: analysis of evidence from 1982\u20132009. Glob Health Sci Pract. 2013;1:203\u201312.","journal-title":"Glob Health Sci Pract"},{"key":"4687_CR28","unstructured":"KENPHIA 2018 Preliminary Report. https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2020\/04\/KENPHIA-2018_Preliminary-Report_final-web.pdf (accessed 20 Feb2025)."},{"key":"4687_CR29","doi-asserted-by":"publisher","first-page":"e25626","DOI":"10.1002\/jia2.25626","volume":"23","author":"K Gill","year":"2020","unstructured":"Gill K, Happel A-U, Pidwell T, Mendelsohn A, Duyver M, Johnson L, et al. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in cape town, as a proxy for HIV prevention methods (UChoose). J Int AIDS Soc. 2020;23:e25626.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR30","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1007\/s10461-021-03571-8","volume":"26","author":"WC Irie","year":"2022","unstructured":"Irie WC, Calabrese SK, Patel RR, Mayer KH, Geng EH, Marcus JL. Preferences for HIV preexposure prophylaxis products among black women in the U.S. AIDS Behav. 2022;26:2212\u201323.","journal-title":"AIDS Behav"},{"key":"4687_CR31","doi-asserted-by":"publisher","first-page":"e25094","DOI":"10.1002\/jia2.25094","volume":"21","author":"A van der Straten","year":"2018","unstructured":"van der Straten A, Agot K, Ahmed K, Weinrib R, Browne EN, Manenzhe K, et al. The tablets, ring, injections as options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. J Int AIDS Soc. 2018;21:e25094.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR32","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1007\/s10461-020-02808-2","volume":"24","author":"EE Tolley","year":"2020","unstructured":"Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, et al. Acceptability of Long-Acting injectable cabotegravir (CAB LA) in HIV-Uninfected individuals: HPTN 077. AIDS Behav. 2020;24:2520\u201331.","journal-title":"AIDS Behav"},{"key":"4687_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s10461-021-03159-2","volume":"25","author":"A Ogunbajo","year":"2021","unstructured":"Ogunbajo A, Storholm ED, Ober AJ, Bogart LM, Reback CJ, Flynn R, et al. Multilevel barriers to HIV PrEP uptake and adherence among black and Hispanic\/Latinx transgender women in Southern California. AIDS Behav. 2021;25:2301\u201315.","journal-title":"AIDS Behav"},{"key":"4687_CR34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10461-014-0950-5","volume":"19","author":"ET Montgomery","year":"2015","unstructured":"Montgomery ET, van der Straten A, Stadler J, Hartmann M, Magazi B, Mathebula F, et al. Male partner influence on women\u2019s HIV prevention trial participation and use of pre-exposure prophylaxis: the importance of Understanding. AIDS Behav. 2015;19:784\u201393.","journal-title":"AIDS Behav"},{"key":"4687_CR35","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a Dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159.","journal-title":"AIDS"},{"key":"4687_CR36","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1097\/QAI.0000000000002587","volume":"86","author":"J Pintye","year":"2021","unstructured":"Pintye J, O\u2019Malley G, Kinuthia J, Abuna F, Escudero JN, Mugambi M, et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: A qualitative evaluation from a PrEP implementation program. J Acquir Immune Defic Syndr 1999. 2021;86:e83\u20139.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"4687_CR37","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s10461-019-02707-1","volume":"24","author":"ST Roberts","year":"2020","unstructured":"Roberts ST, Nair G, Baeten JM, Palanee-Philips T, Schwartz K, Reddy K, et al. Impact of male partner involvement on women\u2019s adherence to the Dapivirine vaginal ring during a phase III HIV prevention trial. AIDS Behav. 2020;24:1432\u201342.","journal-title":"AIDS Behav"},{"key":"4687_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/09540121.2019.1623374","volume":"32","author":"T Chemnasiri","year":"2020","unstructured":"Chemnasiri T, Varangrat A, Amico KR, Chitwarakorn A, Dye BJ, Grant RM, et al. Facilitators and barriers affecting PrEP adherence among Thai men who have sex with men (MSM) in the HPTN 067\/ADAPT study. AIDS Care. 2020;32:249\u201354.","journal-title":"AIDS Care"},{"key":"4687_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/09540121.2012.748871","volume":"25","author":"A Tangmunkongvorakul","year":"2013","unstructured":"Tangmunkongvorakul A, Chariyalertsak S, Amico KR, Saokhieo P, Wannalak V, Sangangamsakun T, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25:961\u20137.","journal-title":"AIDS Care"},{"key":"4687_CR40","doi-asserted-by":"publisher","first-page":"e25463","DOI":"10.1002\/jia2.25463","volume":"23","author":"J Velloza","year":"2020","unstructured":"Velloza J, Khoza N, Scorgie F, Chitukuta M, Mutero P, Mutiti K, et al. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. J Int AIDS Soc. 2020;23:e25463.","journal-title":"J Int AIDS Soc"},{"key":"4687_CR41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11904-018-0385-0","volume":"15","author":"SA Golub","year":"2018","unstructured":"Golub SA. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV\/AIDS Rep. 2018;15:190\u20137.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4687_CR42","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1007\/s10461-012-0317-8","volume":"17","author":"EM Van der Elst","year":"2013","unstructured":"Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17:2162\u201372.","journal-title":"AIDS Behav"},{"key":"4687_CR43","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s10461-018-2102-9","volume":"22","author":"CT Rael","year":"2018","unstructured":"Rael CT, Martinez M, Giguere R, Bockting W, MacCrate C, Mellman W, et al. Barriers and facilitators to oral PrEP use among transgender women in new York City. AIDS Behav. 2018;22:3627\u201336.","journal-title":"AIDS Behav"},{"key":"4687_CR44","unstructured":"What do young women in Africa want for HIV prevention? They want choice.| Microbicide Trials Network. https:\/\/www.mtnstopshiv.org\/news\/what-do-young-women-africa-want-hiv-prevention-they-want-choice (accessed 27 Mar2023)."},{"key":"4687_CR45","unstructured":"The HIV Prevention Trials Network HPTN 084 Open Label Extension FAQ. https:\/\/www.hptn.org\/sites\/default\/files\/inline-files\/HPTN%20084%20OLE%20FAQ_V1.0_Aug2021.pdf (accessed 18 Dec2023)."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04687-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04687-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T02:52:39Z","timestamp":1751856759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04687-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,24]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4687"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04687-x","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"type":"print","value":"1090-7165"},{"type":"electronic","value":"1573-3254"}],"subject":[],"published":{"date-parts":[[2025,3,24]]},"assertion":[{"value":"11 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}